Molecular mechanisms in melanoma [20]

New England Journal of Medicine

Volumn 355, Issue 13, 2006, Pages 1395-1396

  Ugurel, Selma ^a   Houben, Roland ^b   Becker, Jürgen C ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; TUMOR MARKER;

CANCER SURGERY; CHEMOSENSITIVITY; DISEASE MARKER; GENE AMPLIFICATION; GENETIC LINKAGE; HUMAN; LETTER; MELANOMA; METASTASIS; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NOTE; SKIN TUMOR; CELL TRANSFORMATION; MELANOCYTE; NEVUS; PATHOLOGY; RISK FACTOR;

GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; SKIN NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; MELANOCYTES; NEVUS; RISK FACTORS;

EID: 33749045724     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc062093     Document Type: Letter

References (3)

1. McGill GG, Horstmann M, Widlund HR, et al. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 2002;109:707-18.
2. Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005;436:117-22.
3. Ugurel S, Schadendorf D, Pföhler C, et al. In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma - a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). Clin Cancer Res (in press).